ReviewProbiotics and antimicrobial proteins2026
Microbiome-Targeted Probiotic Strategies for the Prevention and Treatment of Osteomyelitis: A Novel Biological Approach.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics analysis: Gut microbial metabolites in ovarian lesions.The Journal of international medical research · 2026Article
- Nutritional support in bone infections: mechanisms, strategies, and clinical practice.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteomyelitis is a serious and often chronic inflammatory bone infection, predominantly caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA), as well as other pathogens such as Pseudomonas aeruginosa and Escherichia coli. It presents significant clinical challenges due to its complex pathophysiology, high relapse rates, and the emergence of antimicrobial resistance. Conventional treatment typically involves prolonged courses of high-dose intravenous antibiotics and surgical debridement, which are invasive, costly, and frequently associated with antimicrobial resistance, adverse effects, and poor patient adherence. This review explores novel probiotic-based biological strategies as a promising alternative for the prevention and treatment of osteomyelitis, with a particular focus on modulating the host microbiome. Probiotics, defined as live microorganisms that confer health benefits to the host, play a critical role in maintaining gut microbiota balance, enhancing immune responses, and improving mucosal barrier integrity. In the context of osteomyelitis, probiotics may prevent infection by enhancing gut barrier integrity, reducing bacterial translocation into the bloodstream and subsequent penetration into the bones, and inhibiting pathogen colonization and biofilm formation on bone and implant surfaces. Additionally, probiotic-derived metabolites such as bacteriocins and organic acids exhibit direct antimicrobial activity. They also compete with pathogens for nutrients and adhesion sites. Importantly, probiotics may promote osteogenic differentiation and bone regeneration through immune modulation. This probiotic-based approach offers a safe, sustainable, and host-friendly strategy for both the prevention and treatment of osteomyelitis, potentially reducing reliance on antibiotics and helping in mitigating the risk of antimicrobial resistance.
Indexed as
Identifiers
41091405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.